Press release

Siemens Healthineers with strong performance in a challenging environment

Siemens Healthineers AG today announced its results for the fourth quarter of fiscal year 2020 that ended September 30, 2020.

Fiscal Year 2020 - Resilient performance in unprecedented times

  • Siemens Healthineers achieves updated outlook from August 2, 2020
  • Equipment book-to-bill ratio at a good 1.06 despite COVID-19 pandemic
  • Revenue of €14.5 billion; year-over-year stable development on a comparable basis
  • Slight comparable revenue growth in Imaging and Advanced Therapies, moderate decline in Diagnostics
  • Adjusted EBIT margin declines by 170 bps to 15.4%, mainly due to COVID-19 effects in Diagnostics
  • Adjusted basic earnings per share down 7% to €1.59
  • Free cash flow increases significantly by 32% to €1.4 billion; pre-tax: €1.9 billion
  • Proposed dividend of €0.80 per share, corresponding to a pay-out ratio of 60% of net income

Q4 Fiscal Year 2020 – Record in order backlog and strong free cash flow

  • Equipment book-to-bill ratio at a very good 1.15, supported by major long-term contracts for “Value Partnerships” in the U.S.
  • Revenue declines 2.0% on a comparable basis from a very strong prior-year quarter
  • Slight comparable revenue drop in Imaging and Diagnostics, Advanced Therapies with strong decline
  • Adjusted EBIT margin decreases by 280 bps to 16.1%, mainly due to COVID-19 effects in Diagnostics
  • Adjusted basic earnings per share down 11% to €0.48
  • Continued strong free cash flow development, with a year-over-year increase of 12% to €708 million

Outlook¹ for Fiscal Year 2021

  • Comparable revenue growth of 5% to 8% expected
  • Adjusted earnings per share between €1.58 and €1.72

1

Siemens Healthineers 2020

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalising healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion.